Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.

Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N.

Breast Cancer Res Treat. 2016 Jul;158(1):67-77. doi: 10.1007/s10549-016-3849-1. Epub 2016 Jun 10.

2.

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.

Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW.

Breast Cancer Res Treat. 2013 Nov;142(2):389-98. doi: 10.1007/s10549-013-2739-z. Epub 2013 Oct 29.

3.

The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women.

Ji Y, Rounds T, Crocker A, Sussman B, Hovey RC, Kingsley F, Muss HB, Garber JE, Wood ME.

Cancer Prev Res (Phila). 2016 May;9(5):379-84. doi: 10.1158/1940-6207.CAPR-15-0300. Epub 2016 Feb 23.

4.

Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia.

Pareek A, Chandurkar N, Thulaseedharan NK, Legha R, Agarwal M, Mathur SL, Salkar HR, Pednekar S, Pai V, Sriram U, Khyalappa R, Parmar M, Agrawal N, Dhruv U, Saxena S.

Curr Med Res Opin. 2015 Nov;31(11):2105-17. doi: 10.1185/03007995.2015.1087989. Epub 2015 Oct 8.

PMID:
26371518
5.

Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.

Arun B, Valero V, Liu D, Brewster A, Green M, Gutierrez-Barrera A, Akar U, Rivera E, Esteva FJ, Buzdar AU, Hortobagyi GN, Sneige N.

Cancer Prev Res (Phila). 2012 Feb;5(2):276-82. doi: 10.1158/1940-6207.CAPR-11-0346. Epub 2011 Nov 18.

6.

Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.

Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators.

Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.

PMID:
19167589
7.

Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.

Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A.

Atherosclerosis. 2015 Apr;239(2):439-43. doi: 10.1016/j.atherosclerosis.2015.02.003. Epub 2015 Feb 7.

PMID:
25697576
8.

Contribution of apolipoprotein A-I to the reduction in high-sensitivity C-reactive protein levels by different statins: comparative study of pitavastatin and atorvastatin.

Tani S, Takahashi A, Nagao K, Hirayama A.

Heart Vessels. 2015 Nov;30(6):762-70. doi: 10.1007/s00380-014-0554-z. Epub 2014 Jul 26.

PMID:
25062713
9.

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.

Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V.

Breast Cancer Res Treat. 2012 Feb;131(3):915-24. doi: 10.1007/s10549-011-1858-7. Epub 2011 Nov 11.

10.

Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials.

Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF.

J Cell Biochem Suppl. 1997;28-29:101-10.

PMID:
9589354
11.

Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.

Navarro JF, Mora C, Muros M, García-Idoate G.

Nephron Clin Pract. 2003;95(4):c128-35.

PMID:
14694274
12.

Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.

Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S.

Heart Vessels. 2008 Jul;23(4):249-56. doi: 10.1007/s00380-008-1038-9. Epub 2008 Jul 23.

PMID:
18649055
13.

Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers.

Shafik NM, Baalash A, Ebeid AM.

Biol Trace Elem Res. 2017 Dec;180(2):255-264. doi: 10.1007/s12011-017-1010-6. Epub 2017 Apr 13.

PMID:
28409410
14.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B.

Breast Cancer Res. 2013 Jun 20;15(3):R47. doi: 10.1186/bcr3439.

15.

The selective estrogen receptor modulators in breast cancer prevention.

Li F, Dou J, Wei L, Li S, Liu J.

Cancer Chemother Pharmacol. 2016 May;77(5):895-903. doi: 10.1007/s00280-016-2959-0. Epub 2016 Jan 20. Review.

PMID:
26787504
16.

Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model.

Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, Mayo MS.

J Natl Cancer Inst. 2000 Aug 2;92(15):1217-27.

PMID:
10922407
17.

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.

Kimura G, Kasahara M, Ueshima K, Tanaka S, Yasuno S, Fujimoto A, Sato T, Imamoto M, Kosugi S, Nakao K.

Clin Exp Nephrol. 2017 Jun;21(3):417-424. doi: 10.1007/s10157-016-1304-6. Epub 2016 Jul 8.

18.

Identification of a chemoprevention cohort from a population of women at high risk for breast cancer.

Fabian CJ, Kamel S, Zalles C, Kimler BF.

J Cell Biochem Suppl. 1996;25:112-22.

PMID:
9027607
19.

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B.

J Clin Oncol. 2009 Aug 10;27(23):3749-56. doi: 10.1200/JCO.2008.19.3797. Epub 2009 Jul 13.

20.

The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.

Keleş T, Akar Bayram N, Kayhan T, Canbay A, Sahin D, Durmaz T, Ozdemir O, Aydoğdu S, Diker E.

Anadolu Kardiyol Derg. 2008 Dec;8(6):407-12.

Supplemental Content

Support Center